Veradermics, Inc. (MANE)
98.75
+1.00
(+1.02%)
USD |
NYSE |
Sep 04, 10:44
Veradermics Cash from Investing (Quarterly) : -277.29M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -277.29M |
| March 31, 2026 | -101.30M |
| December 31, 2025 |
| Date | Value |
|---|---|
| June 30, 2025 | -8.33M |
| March 31, 2025 | -15.75M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -15.40B |
| EyePoint, Inc. | 75.10M |
| Elanco Animal Health, Inc. | -110.00M |
| Tarsus Pharmaceuticals, Inc. | 37.88M |
| Amylyx Pharmaceuticals, Inc. | -149.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.49M |
| Cash from Financing (Quarterly) | 442.70M |
| Free Cash Flow Per Share (Quarterly) | -0.3473 |
| Free Cash Flow to Equity (Quarterly) | -14.94M |
| Free Cash Flow to Firm (Quarterly) | -14.51M |